261952-24-3

Basic information

• Product Name: 4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE
• Synonyms: 4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE;AMINO-(4-TRIFLUOROMETHOXY-PHENYL)-ACETIC ACID;2-AMINO-2-(4-TRIFLUOROMETHOXYPHENYL)ACETIC ACID;4-(Trifluoromethoxy)-DL-phenyl;2-(4-Trifluoromethyloxyphenyl)-glycine;2-Amino-2-(4-(trifluoromethoxy)
• CAS NO: 261952-24-3
• Molecular Formula: C₉H₈F₃NO₃
• Molecular Weight: 235.16
• Product Categories: pharmacetical
• Mol File: 261952-24-3.mol
• Article Data: 5

Chemical Properties

• Melting Point: ca 292℃ subl.
• Boiling Point: 294°Cat760mmHg
• Flash Point: 131.6°C
• Appearance: /
• Density: 1.454g/cm³
• Vapor Pressure: 0.00076mmHg at 25°C
• Refractive Index: 1.506
• PKA: 1.74±0.10(Predicted)
• CAS DataBase Reference: 4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE(261952-24-3)
• EPA Substance Registry System: 4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE(261952-24-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 261952-24-3(Hazardous Substances Data)

Usage

General Description

4-(Trifluoromethoxy)-DL-Phenylglycine is a chemical compound with molecular formula C10H10F3NO3. Commonly referred to as a trifluoromethoxy derivative of phenylglycine, this compound belongs to the class of organic compounds known as phenylglycines and derivatives. These are compounds containing a phenylglycine moiety, which consists of a phenyl group substituted by a glycine. The applied potential uses of 4-(Trifluoromethoxy)-DL-Phenylglycine in scientific research or specific industries are not widely documented or commonly known, indicating it is primarily used for highly specialized or experimental purposes.

InChI:InChI=1/C9H8F3NO3/c10-9(11,12)16-6-3-1-5(2-4-6)7(13)8(14)15/h1-4,7H,13H2,(H,14,15)

Upstream product

• 659-28-9 p-trifluoromethoxybenzaldehyde 
• 954582-33-3 amino(4-(trifluoromethoxy)phenyl)acetonitrile 

Downstream Products

• 348081-33-4 (R)-N-formyl-4-trifluoromethoxyphenylglycine 

Relevant articles and documents

Discovery of a novel series of pyrazolo[1,5-a]pyrimidine-based phosphodiesterase 2A inhibitors structurally different from N-((1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the treatment of cognitive disorders

It has been hypothesized that selective inhibition of phosphodiesterase (PDE) 2A could potentially be a novel approach to treat cognitive impairment in neuropsychiatric and neurodegenerative disorders through augmentation of cyclic nucleotide signaling pathways in brain regions associated with learning and memory. Following our earlier work, this article describes a drug design strategy for a new series of lead compounds structurally distinct from our clinical candidate 2 (TAK-915), and subsequent medicinal chemistry efforts to optimize potency, selectivity over other PDE families, and other preclinical properties including in vitro phototoxicity and in vivo rat plasma clearance. These efforts resulted in the discovery of N-((1S)-2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methyl-5-(3-methyl-1H-1,2,4triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (20), which robustly increased 3′,5′-cyclic guanosine monophosphate (cGMP) levels in the rat brain following an oral dose, and moreover, attenuated MK-801-induced episodic memory deficits in a passive avoidance task in rats. These data provide further support to the potential therapeutic utility of PDE2A inhibitors in enhancing cognitive performance.

Heterocyclic compound

A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer’s disease and the like.

NITROGENATED HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.